stooocks.com

Understand any stock in simple English

Arcus Biosciences, Inc.

United States · NYSE: RCUS · Market cap: · P/E: · P/S:

Arcus Biosciences develops and sells cancer immunotherapies and treatments for inflammatory and autoimmune diseases.

Arcus Biosciences is a drug developer that focuses on the immune system — specifically, on helping the body's own defenses recognize and attack cancer cells. Its main bet is on a class of drugs that block a molecule called adenosine, which tumors use like a cloaking device to shut down immune cells that would otherwise attack them. By cutting that signal, Arcus hopes to make tumors visible to the immune system again, especially in cancers that have resisted existing immunotherapies.

The company earns money mainly through partnerships and licensing deals rather than selling its own approved medicines, because it does not yet market a product of its own. Its biggest ally is Gilead Sciences, which has invested cash and taken a stake in the company, and the two have worked together on a portfolio of programs across cancer and inflammatory disease. That structure is common in biotech: a smaller, science-driven firm does the early discovery work, and a larger partner provides money, expertise, and eventually commercial reach. Arcus also collects revenue from other collaborations, which helps fund its research without forcing it to raise money constantly on its own. The science is the real product. Arcus runs clinical trials testing combinations of its experimental drugs, aiming to show they improve on what is already available. Its lead programs include antibodies and small molecules designed to work together rather than alone, which is a common strategy in immuno-oncology: one drug may prime the immune system while another removes a brake on it. The company is headquartered in Hayward, California, in the Bay Area biotech corridor, close to the academic and research talent that feeds the industry.


Being a clinical-stage biotech means the risks are large and obvious. Arcus spends heavily on research and development, does not have a steady stream of product sales, and depends on trial results that can fail at any stage. Its cash position and partnership money dictate how many shots on goal it can take. Success would mean approval of a new cancer or autoimmune therapy; failure would mean writing off years of expensive work. That binary nature is the honest heart of the business: it is a research bet financed by partnerships, and its value rises or falls on data.

Saved answer · last researched 17 Nov 2026